Literature DB >> 8666430

Granulocyte-macrophage colony-stimulating factor antagonizes the transforming growth factor-beta-induced expression of Fc gamma RIII (CD16) on human monocytes.

M Kruger1, L Coorevits, T P De Wit, M Casteels-Van Daele, J G Van De Winkel, J L Ceuppens.   

Abstract

Fc-gamma receptor III (Fc gamma RIII, CD16) type A is expressed on natural killer cells, on a small subset of peripheral blood monocytes and on mature macrophages. Along with differentiation into macrophages, monocytes will express Fc gamma RIII when cultured with transforming growth factor-beta (TGF-beta). In view of the involvement of granulocyte-macrophage colony-stimulating factor (GM-CSF) in myeloid cell differentiation, we investigated the effect of this cytokine on Fc gamma RIII expression in cultures of peripheral blood monocytes. GM-CSF antagonized TGF-beta-induced expression of Fc gamma RIII on monocytes in vitro in a dose-dependent way. The effect of GM-CSF persisted in cultures until at least day 7. The suppression was at the mRNA level, as shown by Northern analyses with a CD16 specific probe, and the signalling pathway involved tyrosine kinase activity. Interferon-gamma and interleukin-2 had no effect on the induced expression of Fc gamma RIII by TGF-beta, while interleukin-4, similar to GM-CSF, antagonized this induction. Our findings suggest that regulatory cytokine networks can drive monocytes into different effector functions and differentiation pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666430      PMCID: PMC1383983     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells.

Authors:  B Perussia; G Trinchieri
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

3.  Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

Authors:  C W Czarniecki; H H Chiu; G H Wong; S M McCabe; M A Palladino
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

4.  Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.

Authors:  V C Broudy; K Kaushansky; J M Harlan; J W Adamson
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

5.  Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function.

Authors:  H G Fischer; S Frosch; K Reske; A B Reske-Kunz
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

6.  Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor.

Authors:  R Munker; J Gasson; M Ogawa; H P Koeffler
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

7.  Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation.

Authors:  A Wodnar-Filipowicz; C H Heusser; C Moroni
Journal:  Nature       Date:  1989-05-11       Impact factor: 49.962

8.  Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10.

Authors:  R de Waal Malefyt; C G Figdor; R Huijbens; S Mohan-Peterson; B Bennett; J Culpepper; W Dang; G Zurawski; J E de Vries
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

9.  CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes.

Authors:  S B Clarkson; P A Ory
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody.

Authors:  S B Clarkson; R P Kimberly; J E Valinsky; M D Witmer; J B Bussel; R L Nachman; J C Unkeless
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more
  5 in total

1.  IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasis.

Authors:  Matthew R Macey; Jamie L Sturgill; Johanna K Morales; Yves T Falanga; Joshua Morales; Sarah K Norton; Nitin Yerram; Hoon Shim; Josephine Fernando; Alasdair M Gifillan; Gregorio Gomez; Lawrence Schwartz; Carole Oskeritzian; Sarah Spiegel; Daniel Conrad; John J Ryan
Journal:  J Immunol       Date:  2010-03-19       Impact factor: 5.422

2.  Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.

Authors:  Emma Tippett; Wan-Jung Cheng; Clare Westhorpe; Paul U Cameron; Bruce J Brew; Sharon R Lewin; Anthony Jaworowski; Suzanne M Crowe
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

3.  Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer.

Authors:  Dominic Schauer; Patrick Starlinger; Christian Reiter; Nikolaus Jahn; Philipp Zajc; Elisabeth Buchberger; Thomas Bachleitner-Hofmann; Michael Bergmann; Anton Stift; Thomas Gruenberger; Christine Brostjan
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

4.  Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics.

Authors:  Evaggelia Liaskou; Henning W Zimmermann; Ka-Kit Li; Ye H Oo; Shankar Suresh; Zania Stamataki; Omar Qureshi; Patricia F Lalor; Jean Shaw; Wing-kin Syn; Stuart M Curbishley; David H Adams
Journal:  Hepatology       Date:  2012-12-04       Impact factor: 17.425

5.  The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Ronald M Liebman; Knut Schäkel
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.